Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Microbiology Spectrum|July 13, 2026
Effects of elexacaftor/tezacaftor/ivacaftor on the nasal microbial metagenome in cystic fibrosisTom L Hertramph, Marie Dorda, Sophia T Pallenberg, et al.
Frontiers in Medicine|January 23, 2023
TRACK-CF prospective cohort study: Understanding early cystic fibrosis lung diseaseEva Steinke, Olaf Sommerburg, Simon Y Graeber, et al.
International Archives of Allergy and Immunology|December 18, 2009
A Toll-like receptor 2/6 agonist reduces allergic airway inflammation in chronic respiratory sensitisation to Timothy grass pollen antigensBarbara Fuchs, Saskia Knothe, Sabine Rochlitzer, et al.
The European Respiratory Journal|April 10, 2025
Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for <i>F508del</i> and a minimal function mutation: Results from a 96-week open-label extension studyMarcus A Mall, Claire E Wainwright, Julian Legg, et al.
Klinische Padiatrie|January 31, 2022
The First 4 Years - Outcome of Children Identified by Newborn Screening for CF in GermanyKatharina Schütz, Julia Kontsendorn, Nils Janzen, et al.
Journal of Magnetic Resonance Imaging : JMRI|November 28, 2020
Flow Volume Loop and Regional Ventilation Assessment Using Phase-Resolved Functional Lung (PREFUL) MRI: Comparison With <sup>129</sup> Xenon Ventilation MRI and Lung Function TestingTill F Kaireit, Agilo Kern, Andreas Voskrebenzev, et al.
Pediatrics|April 19, 2005
NEMO mutations in 2 unrelated boys with severe infections and conical teethCheng-Lung Ku, Sophie Dupuis-Girod, Anna-Maria Dittrich, et al.
Radiology. Cardiothoracic Imaging|April 4, 2024
PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility StudyMartha Dohna, Andreas Voskrebenzev, Filip Klimeš, et al.
Pediatric Pulmonology|August 22, 2025
Rigid and Flexible Bronchoscopy for Foreign Body Removal in Children: Complications, Risk Factors and Anesthetic ManagementOliver Keil, Yehor Huzhva, Vanessa Rigterink, et al.
Frontiers in Pharmacology|February 13, 2023
Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapyFrauke Stanke, Sophia T Pallenberg, Stephanie Tamm, et al.
Pageof 8